Laddar populära aktier...
The Company has advanced well with its planned activities · Commercial partnership agreement with Proveca Ltd · Good progress with Paed...
· 75 paediatric patients have now been recruited in Study 0202 · Study 0202 is the final required clinical study that will evaluate the...
Selected top 10 investor questions
· Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.
The Company has advanced well with its planned activities · First patient dosed in Paediatric Safety Study 0202 · Superior simulated pa...
· The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 m...
· The US launch is almost there · More paediatric data to be presented at IASP 2024, World Congress on Pain · Commercial partnerships...
The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant a new incentive warrants to existing and new emp...
Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the Company’s extraordinary general meeting.
Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its extraordinary general meeting on Friday 5 July 2024 at 08:30 (CET) a...
· Optimal drug exposure for effective pain management, significant findings revealed that relative drug exposure is much higher in young ...
Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the extraordinary general meeting to be held on Friday, 5 July 2024.
· The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and plac...
· First patient has been dosed in Safety Study 0202 of lead candidate CT001.
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2024.
Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Wednesday 27 March 2023 at 09:00 (CET) at ...
Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 27 March 2024.
Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2023, which also includes the fourth qua...
Copenhagen, Denmark, January 30, 2024 - Today, Cessatech A/S ("Cessatech” or the "Company") announces the outcome of the exercise of warrant...
In the press release published earlier today the MAR label was placed by mistake.
Copenhagen, Denmark, January 23, 2024 - Tomorrow, January 24, 2024, is the last day of trading in warrants of series TO2 (the "Warrants").
Copenhagen, Denmark, January 22, 2024 – Cessatech A/S ("Cessatech" or the "Company") announces that all members of the Company’s Senior Mana...
Copenhagen, Denmark, January 12, 2024 – Cessatech A/S ("Cessatech" or the "Company") announces that today begins the exercise period for the...
Copenhagen, Denmark, January 11, 2024 – Cessatech A/S (“Cessatech” or the "Company") announces that the exercise price for the warrants of s...
On 4 January – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based all the positive fee...
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2023.
· The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number of children required in the final safety study (02...
· Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of CT001 relative to placebo and two comp...
· The Paediatric Committee (PDCO) under The European Medicines Agency (EMA) has agreed to the Paediatric Investigational Plan (PIP) for C...
· US co-development and commercialization partnership signed for CT001 - potential income already from 2024 · Strong clinical progress ...
· Loan facility agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S, which includes some existing share...
On 30 June – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based all the positive feedb...
· Cessatech and Ventis Pharma enter a co-development and commercialization royalty license agreement for CT001 sharing net profits · CT...
· The ongoing stability studies of CT001 have provided confidence in achieving a shelf life of more than two years at controlled room tem...
· Study 0205 is progressing, with last patient expected in Q3 · Protocol finalized for study 0202, ready for submission in Q2 · Good ...
We are well into 2023 and are progressing with our plans.
The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has appointed Martin Olin as new Chairman of the Board
Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Thursday 23 March 2023 at 09:00 (CET) at t...
Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 23 March 2023.
Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2022, which also includes the fourth qua...
We welcome the year 2023 which is a very exiting year for Cessatech, we are expecting many milestone and we want to give you and update on o...
The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant new incentive warrants to existing and new emplo...
Copenhagen, Denmark, December 7, 2022 – On November 24, 2022, Cessatech A/S (“Cessatech” or the “Company”) announced the resolution of the b...
København, Denmark, November 24, 2022 – At a board meeting today the board of directors in Cessatech A/S (“Cessatech” or the “Company”) reso...
København, Denmark, November 18, 2022 – The rights issue announced on October 19, 2022 in Cessatech A/S has been registered with the Danish ...
· Successful outcome of trial 0206, a phase 2 pharmacokinetics trial in children undergoing elective surgical procedures · First patien...
København, Denmark, November 14, 2022 – The results of the rights issue announced on October 19, 2022 for which the subscription period ende...
København, Denmark, November 8, 2022 – Cessatech A/S (“Cessatech” or the “Company”) announces that the subscription period for the Company’s...
Cessatech A/S, CVR no. 41 29 30 55 (“Cessatech” or the “Company”) held an extraordinary general meeting on Friday 4 November 2022, at 8:00 (...
København, Denmark, October 27, 2022 – Cessatech A/S (“Cessatech” or the “Company”) announces that the subscription period for the Company’s...
Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the extraordinary general meeting to be held on Friday 4 November 2022.
København, Denmark, October 20, 2022 – Cessatech A/S (“Cessatech” or the “Company”) today released the Offering Memorandum in connection wit...
København, Denmark, October 19, 2022 – The Board of Directors of Cessatech A/S (“Cessatech” or the “Company”) has today resolved to carry ou...
Great progress during Q3 – more to come
· Clinical trial 0206 investigated the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.
· First patient has been dosed in pivotal trial of lead candidate CT001 · The pivotal trial, trial 0205, will investigate the postopera...
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2022.
We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that w...
· Trial 0205, the pivotal trial, will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted...
· Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2022.
Newsletter #6 - Mar 2022
Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Thursday 17 March 2022 at 08:00 (CET) as a...
Topline results of clinical trial 0204 investigating the absolute bioavailability of CT001 showed clinical relevant exposures following nasa...
Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2021.
The shareholders of Cessatech A/S The board of directors hereby convenes the annual general meeting of Cessatech to be held on Thursday 17 ...
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 October – 31 December 2021.
Topline results of clinical trial 0204 in healthy volunteers investigating the absolute bioavailability of CT001, which was set to be announ...
Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with the intention that she will be proposed as a membe...
Copenhagen, Denmark, 4 January 2022 – On Thursday, 16 December 2021, the exercise period for Cessatech A/S ("Cessatech" or the “Company") wa...
Newsletter update #5 - Dec 2021
During the period 25 November – 16 December 2021, holders of TO 1 have been entitled to subscribe for shares with warrants.
Copenhagen, Denmark, 14 December 2021 – Tuesday, 14 December 2021, is the last day of trading in warrants of series TO 1 on Spotlight Stock ...
Copenhagen, Denmark, 8 December 2021 – The CEO and members of the Board of Directors of Cessatech A/S (“Cessatech” or the “Company”) have ex...
Copenhagen, Denmark, 25 November 2021 – Today, 25 November 2021, marks the beginning of the exercise period for the warrants of series TO 1 ...
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2021.
Preparing for next year... We continue to make good progress with the clinical activities for CT001, and 2022 will be a very interesting yea...
Copenhagen, Denmark, 02 November 2021 – Cessatech A/S (“Cessatech” or the “Company”) announces that the United States Patent and Trademark O...
Clinical trial 0206 will investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures.
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2021.
We continue to make firm progress with the clinical activities for CT001.
The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has appointed Adam Steensberg as new Chairman of the Board.
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports last subject dosed ahead of timeli...
Among the 26 micro-companies, the IPO guide's reviewers found an average of 2.
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2021.
Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Friday 26 March 2021 at 08:00 (CET) at Kan...
Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001.
Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2020.
The shareholders of Cessatech A/S The board of directors hereby convenes the annual general meeting of Cessatech to be held on Friday 26 Ma...
CFI.co - a journal and online resource reporting on business, economics and finance - announced that Cessatech A/S (“Cessatech”) won the 202...
First major milestone reached: Data from the Registry Safety Study (0203) Cessatech A/S announces positive, top line data from a retrospecti...
